HighTower Advisors
IMNM icon

HighTower Advisors’s Immunome IMNM Stock Holding History

HighTower Advisors’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,403
Closed -$206K – 3918
2026
Q1 		$206K Sell
9,403
-1,628
-15% -$36.2K ﹤0.01% 3460
2025
Q4 		$237K Sell
11,031
-1,501
-12% -$26.3K ﹤0.01% 3224
2025
Q3 		$147K Sell
12,532
-126
-1% -$1.25K ﹤0.01% 3461
2025
Q2 		$118K Buy
+12,658
New +$104K ﹤0.01% 3436
2024
Q1 		– Sell
-16,818
Closed -$180K – 3816
2023
Q4 		$180K Sell
16,818
-2,000
-11% -$16.6K ﹤0.01% 3046
2023
Q3 		$157K Buy
18,818
+3,000
+19% +$22K ﹤0.01% 2997
2023
Q2 		$126K Sell
15,818
-1,000
-6% -$5.47K ﹤0.01% 3024
2023
Q1 		$83K Buy
+16,818
New +$82.3K ﹤0.01% 2977

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

HighTower Advisors's IMNM Position: Q2 2026 in Review

HighTower Advisors sold out of Immunome (IMNM) in Q2 2026, closing a stake of 9,403 shares — an estimated $206K sold.

HighTower Advisors first reported a position in IMNM in Q1 2023 and held it in 8 quarters. The position peaked at $237K in Q4 2025. 203 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • HighTower Advisors reported no remaining Immunome position as of Q2 2026 after selling out during the quarter.
  • HighTower Advisors sold 9,403 Immunome shares in Q2 2026, an estimated $206K.
  • HighTower Advisors first reported a position in Immunome in Q1 2023 and held it in 8 quarters.
  • HighTower Advisors's Immunome position peaked at $237K in Q4 2025.
  • 203 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.